Patent · US Active

Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant

US10441653B2 · kind B2 · utility

22Cited by

27References

33Claims

0Family size

Assignee

CureVac AG · DE

Inventors

Ingmar Hoerr · Tübingen, DE
Jochen Probst · Wolfschlugen, DE
Thomas Ketterer · Bingen, DE
Birgit Scheel · Tübingen, DE

Key dates

Filing date	Jun 8, 2012
Grant date	Oct 15, 2019
Priority date	—
Expiry date	Feb 14, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a nucleic acid of the general formula (I): GIXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.